[Differential Therapy of Prostate Cancer]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2007 Oct 30

PMID 17965846

Authors

T Jager

H Rubben

C Borgermann

Affiliations

Soon will be listed here.

Abstract

Prostate cancer has become the most common malignancy in males worldwide. Standard therapy in local confined prostate cancer with curative intent is a radical ablation of the gland. Brachytherapy seems to be an alternative treatment but long-term results are not yet available. In cases of advanced disease androgen deprivation is applied to eliminate testosterone which is the natural stimulator of tumor growth. The application of chemotherapy is limited to androgen-independent disease without curative intention. Standard chemotherapy is Docetaxel. Both early detection and aftercare are based on measurement of prostate-specific antigen.

References

de Koning H, Liem M, Baan C, Boer R, Schroder F, Alexander F . Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002; 98(2):268-73. DOI: 10.1002/ijc.10188. View

Parkin D, Pisani P, Ferlay J . Global cancer statistics. CA Cancer J Clin. 1999; 49(1):33-64, 1. DOI: 10.3322/canjclin.49.1.33. View

Thompson Jr I, Tangen C, Paradelo J, Lucia M, Miller G, Troyer D . Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006; 296(19):2329-35. DOI: 10.1001/jama.296.19.2329. View

Messing E, Manola J, Yao J, Kiernan M, Crawford D, Wilding G . Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006; 7(6):472-9. DOI: 10.1016/S1470-2045(06)70700-8. View

Catalona W, Smith D, Ratliff T, Basler J . Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993; 270(8):948-54. View

Nomura A, Kolonel L . Prostate cancer: a current perspective. Epidemiol Rev. 1991; 13:200-27. DOI: 10.1093/oxfordjournals.epirev.a036069. View

Marugame T, Katanoda K . International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents Vol. VIII. Jpn J Clin Oncol. 2006; 36(6):399-400. DOI: 10.1093/jjco/hyl049. View

Sasaki H, Miki J, Hasegawa T, Hasegawa N, Ikemoto I, Ohishi Y . [Prostatic cancer in a young adult: a report of 2 cases]. Hinyokika Kiyo. 2004; 50(1):57-9. View

Damber J, Khatami A . Surgical treatment of localized prostate cancer. Acta Oncol. 2005; 44(6):599-604. DOI: 10.1080/02841860510029734. View

10.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

11.

Gann P, Hennekens C, Stampfer M . A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273(4):289-94. View

12.

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L . Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366(9485):572-8. DOI: 10.1016/S0140-6736(05)67101-2. View

13.

Luboldt H, Husing J, Altwein J, Bichler K, Czaja D, Fornara P . [Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group]. Urologe A. 2000; 39(4):330-3. DOI: 10.1007/s001200050365. View

14.

Martinez A, Gonzalez J, Chung A, Kestin L, Balasubramaniam M, Diokno A . A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000; 88(2):425-32. DOI: 10.1002/(sici)1097-0142(20000115)88:2<425::aid-cncr25>3.0.co;2-z. View

15.

Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace D . Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis. 2006; 10(1):87-93. DOI: 10.1038/sj.pcan.4500916. View

16.

Potter S, Carter H . The role of prostate-specific antigen velocity in prostate cancer early detection. Curr Urol Rep. 2002; 1(1):15-9. DOI: 10.1007/s11934-000-0030-4. View

17.

Ellis W, Chetner M, Preston S, Brawer M . Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol. 1994; 152(5 Pt 1):1520-5. DOI: 10.1016/s0022-5347(17)32460-6. View

18.

Patchell R, Tibbs P, Regine W, Payne R, Saris S, Kryscio R . Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005; 366(9486):643-8. DOI: 10.1016/S0140-6736(05)66954-1. View

19.

Jager T, Eisenhardt A, Rubben H, Lummen G . [Does cigarette smoking influence the survival of patients with prostate cancer?]. Urologe A. 2007; 46(4):397-400. DOI: 10.1007/s00120-006-1252-y. View

20.

Hu J, Nelson R, Wilson T, Kawachi M, Ramin S, Lau C . Perioperative complications of laparoscopic and robotic assisted laparoscopic radical prostatectomy. J Urol. 2006; 175(2):541-6. DOI: 10.1016/S0022-5347(05)00156-4. View